Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease - Full Text View

Sponsors and Collaborators:	Baylor College of Medicine Forest Laboratories
Information provided by:	Baylor College of Medicine
ClinicalTrials.gov Identifier:	NCT00646204

Purpose

To evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease.

Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of movement) and tremor. Parkinson's Disease , however, reveals numerous non-motor symptoms that have been underemphasized. Problematic symptoms include varying degrees of dementia, psychosis, diminished assertiveness and confidence, general fatigue, excessive daytime sleepiness, problems with blood pressure, sweating, and bladder, and a common yet difficult to define sense of "not feeling well".

Condition	Intervention	Phase
Parkinson's Disease	Drug: Memantine Drug: placebo	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE

Resource links provided by NLM:

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics: Parkinson's Disease Tremor

Drug Information available for: Memantine Memantine hydrochloride

U.S. FDA Resources

Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:

This is an exploratory study. The primary efficacy point will be global impressions. [ Time Frame: baseline versus study end ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Analyses will be computed for the categorical dependent variables (DV): spirograph, pouring, subjective ADL, observed tremor, global assessment by examiner, global assessment by patient, and subjective assessment by patient scores. [ Time Frame: baseline versus end of study ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	40
Study Start Date:	April 2006
Study Completion Date:	March 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental memantine 10 mg bid	Drug: Memantine 10 mg bid
2: Placebo Comparator 2 tabs bid	Drug: placebo 2 tabs bid

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects must be between the ages of 18 and 80 inclusive.
Each subject must meet standard criteria for PD.
All patients on dopaminergic therapy must report benefit. -No other abnormal neurological signs. -No direct or indirect trauma to the nervous system within 3 months preceding the onset of PD. -No convincing evidence of sudden onset or evidence of stepwise deterioration.
Subjects must be in generally good health as evidenced by previous medical history and clinical examination.
Subjects will be allowed to take any PD medication with the exception of amantadine. They will also be allowed to take medications approved for the use of Alzheimer's disease.
Subjects will be required to be on a stable dose of all medications for at least two weeks prior to entry into the study and may not alter these medications throughout the study.
If subjects are on an anti-depressant medications, a stable dose of these will be required for at least six weeks prior to entry into the study.
Subjects must be accessible by telephone.
If the subject is a female of childbearing age, she must have had: a hysterectomy, or tubal ligation, or otherwise be incapable or pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.
Female of childbearing age must have had a negative urine pregnancy test within one week of study entry. 11. Prior to participation in this study, each subject must sign an informed consent.

Exclusion Criteria:

Subjects who do not meet inclusion criteria.
Subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation.
Subjects who can not maintain an identical dose of any medicine that may affect PD symptoms or signs during their entire study involvement.
Subjects who have exhibited meaningful psychiatric disease not thought to be related to PD. (Depression and psychosis typical for PD will not be excluded). 5. Subjects who have previously taken memantine.

6. Subjects currently taking Amantadine. 7. Subjects with greater than moderate dementia (MMSE<24). 8. Subjects with co-morbid disease that in the investigators decision could interfere with treatment with memantine.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00646204

Locations

United States, Texas
PDCMDC 6550 Fannin, Suite 1801
Houston, Texas, United States, 77030

Sponsors and Collaborators

Baylor College of Medicine

Forest Laboratories

Investigators

Principal Investigator:

William G Ondo, MD

Baylor College of Medicine

More Information

No publications provided

Responsible Party:	Baylor College of Medicine ( William G. Ondo, MD )
Study ID Numbers:	H-18912
Study First Received:	December 28, 2007
Last Updated:	April 30, 2009
ClinicalTrials.gov Identifier:	NCT00646204 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Baylor College of Medicine:

Parkinson's disease
non-motor symptoms

Study placed in the following topic categories:

Excitatory Amino Acids
Neurotransmitter Agents
Ganglion Cysts
Basal Ganglia Diseases
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases

Dopamine
Parkinson Disease
Movement Disorders
Memantine
Dopamine Agents
Parkinsonian Disorders

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Basal Ganglia Diseases
Nervous System Diseases
Antiparkinson Agents
Central Nervous System Diseases
Excitatory Amino Acid Agents
Brain Diseases

Neurodegenerative Diseases
Pharmacologic Actions
Parkinson Disease
Movement Disorders
Therapeutic Uses
Memantine
Dopamine Agents
Parkinsonian Disorders
Central Nervous System Agents
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on July 06, 2009